2021-01-11,Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestones
2021-01-06,Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference
2021-01-05,Replimune Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
2020-12-12,Is REPL A Good Stock To Buy Now?
2020-11-12,Replimune to Participate at the SVB Leerink Oncology 1x1 Day
2020-11-09,Replimune Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference
2020-11-05,Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
2020-10-27,"Is Replimune Group, Inc. (NASDAQ:REPL) Popular Amongst Insiders?"
2020-10-22,Replimune Announces Pricing of Upsized Public Offering
2020-10-20,Replimune Announces Proposed Public Offering
2020-10-20,Replimune Releases Updated Corporate Presentation
2020-10-19,Replimune Appoints Tanya Lewis to the Board of Directors
2020-10-15,Why Replimune Stock Is Soaring Today
2020-10-15,"Benzinga's Top Upgrades, Downgrades For October 15, 2020"
2020-10-14,Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2020-08-07,Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
2020-08-04,Replimune to Present at Two Upcoming Investor Conferences
2020-07-22,"Replimune Appoints Andrea Pirzkall, M.D. as Chief Medical Officer"
2020-06-22,"Replimune Group, Inc. (REPL): Hedge Funds Are Reducing Exposure"
2020-06-17,Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
2020-06-11,Replimune (REPL) Looks Good: Stock Adds 5.8% in Session
2020-06-08,Replimune Announces Pricing of Upsized Public Offering
2020-06-08,Replimune Announces Proposed Public Offering
2020-06-03,Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
2020-06-03,Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimunes Ongoing Registration-Directed Clinical Trials with RP1
2020-04-30,"Replimune to Provide Data Update on June 3, 2020"
2020-04-02,Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors
2020-02-13,Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
2020-02-06,Replimune to Present at Two Upcoming Investor Conferences
2020-01-13,Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones
2020-01-09,Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization
2020-01-07,Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference
2019-12-23,"Replimune Group, Inc. (NASDAQ:REPL): Are Hedge Funds Right About This Stock?"
2019-12-09,Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer
2019-11-26,Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference
2019-11-22,Largest Insider Trades of the Week
2019-11-14,Replimune Announces Pricing of Public Offering
2019-11-12,Replimune Announces Proposed Public Offering
2019-11-11,Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update
2019-11-08,Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)
2019-10-31,Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2019-10-31,"Is Replimune Group, Inc. (REPL) A Good Stock To Buy?"
2019-10-24,Replimune Announces First Patient Enrolled in Phase 1 Clinical Trial of RP2 Alone and in Combination with OpdivoÂ® in Advanced Cancer Patients
2019-10-15,Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma
2019-10-02,Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2019-10-01,Replimune to Present at Chardans 3rd Annual Genetic Medicines Conference
2019-09-13,2 Downtrodden Small Biotechs That Are Showing Signs of Life
2019-08-14,Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update
2019-08-06,Replimune to Present at 2019 Wedbush PacGrow Healthcare Conference
2019-07-19,Imagine Owning Replimune Group (NASDAQ:REPL) And Wondering If The 17% Share Price Slide Is Justified
2019-06-28,Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update
2019-06-01,Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab
2019-05-30,Replimune to Present at Upcoming Investor Conferences
2019-05-16,Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
2019-04-25,"Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation"
2019-04-01,Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019
2019-02-14,"Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update"
2019-02-07,Replimune to Present at Two Upcoming Investor Conferences
2019-01-04,"How Much Are Replimune Group, Inc. (NASDAQ:REPL) Insiders Spending On Buying Shares?"
2019-01-03,Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference
2018-12-20,Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference
2018-12-08,"RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy?"
2018-12-05,Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
2018-11-14,"Bain Capital Life Sciences Investors, LLC Buys Replimune Group Inc"
2018-11-14,"Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update"
2018-09-26,Replimune to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
2018-09-06,"Replimune Announces FDA Acceptance of Investigational New Drug Application for its Lead Oncolytic Immunotherapy Candidate, RP1"
2018-08-30,"Replimune Reports Financial Results for the First Fiscal Quarter, Ended June 30, and Provides Development and Corporate Update"
2018-08-14,BMO Sees A Low-Risk Biotech Buy In Replimune
2018-07-24,[$$] Gormley's Take: Public Markets' Embrace of Health Care Extends Beyond Biotech
